These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24048738)

  • 61. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
    Kim MH; Kim J; Hong H; Lee SH; Lee JK; Jung E; Kim J
    EMBO J; 2016 Mar; 35(5):462-78. PubMed ID: 26668268
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.
    Basile KJ; Abel EV; Aplin AE
    Oncogene; 2012 May; 31(19):2471-9. PubMed ID: 21996740
    [TBL] [Abstract][Full Text] [Related]  

  • 63. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
    Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE
    J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
    Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
    J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fisetin, a dietary flavonoid, induces apoptosis of cancer cells by inhibiting HSF1 activity through blocking its binding to the hsp70 promoter.
    Kim JA; Lee S; Kim DE; Kim M; Kwon BM; Han DC
    Carcinogenesis; 2015 Jun; 36(6):696-706. PubMed ID: 25840992
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
    Goodall ML; Wang T; Martin KR; Kortus MG; Kauffman AL; Trent JM; Gately S; MacKeigan JP
    Autophagy; 2014 Jun; 10(6):1120-36. PubMed ID: 24879157
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
    Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
    Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
    Xiao J; Egger ME; McMasters KM; Hao H
    BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.
    Manzini C; Venè R; Cossu I; Gualco M; Zupo S; Dono M; Spagnolo F; Queirolo P; Moretta L; Mingari MC; Pietra G
    Oncotarget; 2016 Sep; 7(38):60858-60871. PubMed ID: 27563819
    [TBL] [Abstract][Full Text] [Related]  

  • 71. BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activation.
    Anderson LR; Sutherland RL; Butt AJ
    Oncogene; 2010 Jan; 29(4):527-38. PubMed ID: 19881545
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
    Shi H; Moriceau G; Kong X; Lee MK; Lee H; Koya RC; Ng C; Chodon T; Scolyer RA; Dahlman KB; Sosman JA; Kefford RF; Long GV; Nelson SF; Ribas A; Lo RS
    Nat Commun; 2012 Mar; 3():724. PubMed ID: 22395615
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.
    Ji Z; Kumar R; Taylor M; Rajadurai A; Marzuka-Alcalá A; Chen YE; Njauw CN; Flaherty K; Jönsson G; Tsao H
    Clin Cancer Res; 2013 Aug; 19(16):4383-91. PubMed ID: 23812671
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition.
    Fernandez M; Sutterlüty-Fall H; Schwärzler C; Lemeille S; Boehncke WH; Merat R
    Cancer Med; 2017 Jul; 6(7):1652-1664. PubMed ID: 28573821
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
    Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M
    ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.
    Sharma A; Shah SR; Illum H; Dowell J
    Drugs; 2012 Dec; 72(17):2207-22. PubMed ID: 23116250
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
    Lai F; Guo ST; Jin L; Jiang CC; Wang CY; Croft A; Chi MN; Tseng HY; Farrelly M; Atmadibrata B; Norman J; Liu T; Hersey P; Zhang XD
    Cell Death Dis; 2013 Jun; 4(6):e655. PubMed ID: 23744355
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells.
    Martin S; Dudek-Perić AM; Maes H; Garg AD; Gabrysiak M; Demirsoy S; Swinnen JV; Agostinis P
    Biochem Pharmacol; 2015 Feb; 93(3):290-304. PubMed ID: 25529535
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.
    Corazao-Rozas P; Guerreschi P; Jendoubi M; André F; Jonneaux A; Scalbert C; Garçon G; Malet-Martino M; Balayssac S; Rocchi S; Savina A; Formstecher P; Mortier L; Kluza J; Marchetti P
    Oncotarget; 2013 Nov; 4(11):1986-98. PubMed ID: 24161908
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.